Navigation Links
NicOx Announces Departure of Damian Marron for CEO Position
Date:5/27/2008

SOPHIA ANTIPOLIS, France, May 27 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced that Damian Marron, Executive Vice President of Corporate Development, will be leaving the company on May 30th to become Chief Executive Officer of an early clinical stage biopharmaceutical company. Damian's responsibilities will be assumed by Sanjiv Sharma, Vice President Commercial Affairs and Gavin Spencer, Senior Director Business Development.

Michele Garufi, Chairman and CEO of NicOx, commented: "Since joining NicOx in 2002, Damian has made a great contribution to the growth and success of the Company, during which time we have advanced our lead compound naproxcinod into an extensive phase 3 clinical trial program and signed significant collaborative agreements with both Pfizer and Merck, amongst others. Damian has helped to establish a strong corporate development team, which will focus on the next phase of NicOx' development as a fully integrated biopharmaceutical company. We wish Damian every success in this exciting new opportunity with his new company."

Damian Marron said: "It has been a privilege to work at NicOx. During my six years, I have gained invaluable experience and have had the opportunity to broaden my skills such that I have now been offered this great opportunity to lead a biotechnology company. NicOx has established itself as one of Europe's leading biotechnology companies with a highly promising lead product and excellent relationships in the pharmaceutical industry. With a first rate management team in place to execute NicOx' strategy of becoming an integrated pharmaceutical company, I believe this is an excellent time to move on to the new challenge of the role of CEO."

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).


'/>"/>
SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
2. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
3. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
4. NicOx Opens U.S. Headquarters in New Jersey
5. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
6. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
7. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
10. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
11. Amarin Announces Completion of the First Tranche of $60 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as ... private label organic services. , The first organic product is Organic 18 Percent Layer ... Dynamite Marketing, which owns the facility. , Catalyst already has received the Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A ... safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported ... two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on the ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology:
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
Breaking Biology News(10 mins):